

02-5151

# Theralase™ Technologies Inc. Photo-Dynamic Therapy

SUITE 1240 • 70 YORK STREET • TORONTO • ONTARIO • M5J 1S9  
Telephone (416) 368-4440 • Telecopier (416) 865-1382  
e-mail: [theralase@atlantor.com](mailto:theralase@atlantor.com)



05007828

## PRESS RELEASE

FC. \_\_\_\_\_

SUBJECT: **Theralase Technologies Achieves Initial Profitability in 2004**

Toronto; 28 April 2005 -- **Theralase Technologies Inc. (TSXV/NEX: TLT.H & OTC BB:TLTFF)** announced that it recorded its initial operating profitability and a positive cash flow for the year ending December 31, 2004. Gross sales for the year totalled \$657,000, with net income of \$57,000 (nil per share earnings) and a positive cash flow of \$78,000. Prior year comparisons are not meaningful because its wholly-owned operating subsidiary, **Theralase Inc.**, was acquired in November 2003.

The Company attributed its profitable 2004 performance to sharply increased therapeutic laser unit sales spurred by drug safety concerns deriving from the use of Cox-2 inhibitor painkillers, as Vioxx, Celebrex and Bextra. The innovative, proprietary Theralase medical laser units provide safe and effective non-invasive replacement therapy for the management and control of systemic pain.

The Company also pointed to the world's aging demographics which results in the rapidly increasing incidence of painful musculo-skeletal disorders. An aging population will actively embrace the therapeutic relief offered by new and more powerful medical laser technologies.

**Theralase Technologies Inc.** designs, develops, manufactures and sells proprietary, innovative, higher-powered, super-pulsed therapeutic laser equipment for a wide range of applications in photo-dynamic medical therapy. The Theralase technology platform is employed in market-oriented applications in several diverse healthcare sectors -- firstly, for non-invasive pain management, control and therapy applied to treat musculo-skeletal arthritic and rheumatoidal disorders -- secondly, to bio-stimulate and accelerate wound care and healing, including bone fracture regeneration and for osteoporosis conditions -- and thirdly, applying proprietary photo-dynamic laser therapy to attack specially-targeted cancerous growths.

- 30 -

For Further Information -- Contact:  
S. Donald Moore, President  
Phone: (416) 368-4440

PROCESSED

MAY 13 2005

THOMSON  
FINANCIAL

*The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the contents of this release.*

*dlw 5/13*